Skip to main content

Advertisement

SpringerLink
Log in

Changing Pattern of Sedative Use in Older Adults: A Population-Based Cohort Study

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background

Benzodiazepine medications have well-documented side effects, and their prescription rates in older adults have been declining. Trazodone and quetiapine are medications with sedative properties when used at low doses and are commonly used off-label for sleep or behavioral symptoms in older adults.

Objective

Our objective was to describe the shifting patterns of sedative prescription in older adults over time by comparing changes in benzodiazepine, trazodone, and quetiapine dispensing between community and long-term care settings.

Methods

We conducted a population-based serial cross-sectional study to compare the patterns of sedative dispensing (specifically, benzodiazepines, trazodone, and quetiapine) to individuals aged ≥66 years between 1 January 2002 and 31 March 2013 in Ontario, Canada. We compared rates of use between long-term care and community settings and used linear regression models to characterize the magnitude and direction of the rate of change in sedative use by age, sex, and dementia status.

Results

The dispensing of trazodone and quetiapine increased over time, and this coincided with a decrease in benzodiazepine dispensing. This pattern was particularly apparent in the oldest cohort and in those with dementia. Benzodiazepines, trazodone, and quetiapine were associated with high rates of psychotropic polypharmacy. Overall trends were similar in long-term care and the community.

Conclusions

While benzodiazepine prescribing is declining among older adults in Ontario over time, there is a corresponding shift towards low-dose, off-label prescribing of trazodone and quetiapine and psychotropic polypharmacy. These prescribing trends highlight sedative substitution and reinforce the need to confirm efficacy and safety of this practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Salzman C, The APA. Task force report on benzodiazepine dependence, toxicity, and abuse. Am J Psychiatry. 1991;148(2):151–2.

    CAS  PubMed  Google Scholar 

  2. Committee on the Safety of Medicines. Benzodiazepines, dependence and withdrawal syndromes. Curr Probl. 1988;21:1–2.

    Google Scholar 

  3. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med. 1991;151(9):1825–32.

    Article  CAS  PubMed  Google Scholar 

  4. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des. 2002;8(1):45–58.

    Article  CAS  PubMed  Google Scholar 

  6. Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs. 2003;17(11):825–37.

    Article  CAS  PubMed  Google Scholar 

  7. AGS Choosing Wisely Workgroup. American Geriatrics Society identifies another five things that healthcare providers and patients should question. J Am Geriatr Soc. 2014;62(5):950–60.

    Article  Google Scholar 

  8. Fick D, Semla T, Beizer J, Brandt N, Dombrowski R, DuBeau CE, et al. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.

    Article  Google Scholar 

  9. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ. 1997;156(3):385–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8.

    Article  PubMed  Google Scholar 

  11. Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries. Eur J Clin Pharmacol. 2013;69(4):1–10.

    Article  PubMed  Google Scholar 

  12. Stoudemire A, Smith DA. OBRA regulations and the use of psychotropic drugs in long-term care facilities: impact and implications for geropsychiatric care. Gen Hosp Psychiatry. 1996;18(2):77–94.

    Article  CAS  PubMed  Google Scholar 

  13. Kollen BJ, van der Veen WJ, Groenhof F, Donker GA, van der Meer K. Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference? BMC Fam Pract. 2012;13:111.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Rat C, Penhouet G, Gaultier A, Chaslerie A, Pivette J, Nguyen JM, et al. Did the new French pay-for-performance system modify benzodiazepine prescribing practices? BMC Health Serv Res. 2014;14:301.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–8.

    Article  PubMed  Google Scholar 

  16. Tu K, Mamdani MM, Hux JE, Tu JB. Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada. J Am Geriatr Soc. 2001;49(10):1341–5.

    Article  CAS  PubMed  Google Scholar 

  17. Huerta C, Abbing-Karahagopian V, Requena G, Oliva B, Alvarez Y, Gardarsdottir H, et al. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf. 2016;25(Suppl 1):56–65.

    Article  CAS  PubMed  Google Scholar 

  18. Mamdani M, Rapoport M, Shulman KI, Herrmann N, Rochon PA. Mental health-related drug utilization among older adults: prevalence, trends, and costs. Am J Geriatr Psychiatry. 2005;13(10):892–900.

    Article  PubMed  Google Scholar 

  19. Azermai M, Elseviers M, Petrovic M, Van Bortel L, Stichele RV. Geriatric drug utilisation of psychotropics in Belgian nursing homes. Hum Psychopharmacol. 2011;26(1):12–20.

    Article  PubMed  Google Scholar 

  20. Harris T, Carey IM, Shah SM, DeWilde S, Cook DG. Antidepressant prescribing in older primary care patients in community and care home settings in England and Wales. J Am Med Dir Assoc. 2012;13(1):41–7.

    Article  PubMed  Google Scholar 

  21. Verhoeven V, Lopez Hartmann M, Wens J, Sabbe B, Dieleman P, Tsakitzidis G, et al. Happy pills in nursing homes in Belgium: a cohort study to determine prescribing patterns and relation to fall risk. J Clin Gerontol Geriatr. 2014;5(2):53–7.

    Article  Google Scholar 

  22. Bourgeois J, Elseviers MM, Van Bortel L, Petrovic M, Vander Stichele RH. The use of antidepressants in Belgian nursing homes: focus on indications and dosages in the PHEBE study. Drugs Aging. 2012;29(9):759–69.

    Article  PubMed  Google Scholar 

  23. Sultzer DL, Gray KF, Gunay I, Wheatley MV, Mahler ME. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? J Am Geriatr Soc. 2001;49(10):1294–300.

    Article  CAS  PubMed  Google Scholar 

  24. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55(9):1271–8.

    Article  CAS  PubMed  Google Scholar 

  25. Camargos EF, Louzada LL, Quintas JL, Naves JOS, Louzada FM, Nóbrega OT. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. 2014;22(12):1565–74.

    Article  PubMed  Google Scholar 

  26. Cheung G, Stapelberg J. Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials. N Z Med J. 2011;124(1336):39–50.

    PubMed  Google Scholar 

  27. Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5(Suppl 1):S5.

    Article  PubMed  PubMed Central  Google Scholar 

  28. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.

    Article  Google Scholar 

  29. Richardson K, Bennett K, Kenny RA. Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults. Age Ageing. 2015;44(1):90–6.

    Article  PubMed  Google Scholar 

  30. Sirdifield C, Anthierens S, Creupelandt H, Chipchase SY, Christiaens T, Siriwardena AN. General practitioners’ experiences and perceptions of benzodiazepine prescribing: systematic review and meta-synthesis. BMC Fam Pract. 2013;14:191.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Institute for Safe Medication Practices (ISMP) Canada. Safer medication use in older persons information page. https://www.ismp-canada.org/beers_list/. Accessed 4 Aug 2015.

  32. Chan B. Transforming healthcare in Ontario through integration, evidence, and building capacity for improvement. Healthc Manag Forum. 2012;25(4):191–3.

    Article  Google Scholar 

  33. Alessi-Severini S, Bolton JM, Enns MW, Dahl M, Collins DM, Chateau D, et al. Use of benzodiazepines and related drugs in Manitoba: a population-based study. CMAJ Open. 2014;2(4):E208–16.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Snowdon J, Galanos D, Vaswani D. Patterns of psychotropic medication use in nursing homes: surveys in Sydney, allowing comparisons over time and between countries. Int Psychogeriatr. 2011;23(9):1520–5.

    Article  PubMed  Google Scholar 

  35. Ruths S, Sørensen PH, Kirkevold O, Husebø BS, Krüger K, Halvorsen KH, et al. Trends in psychotropic drug prescribing in Norwegian nursing homes from 1997 to 2009: a comparison of six cohorts. Int J Geriatr Psychiatry. 2013;28(8):868–76.

    Article  PubMed  Google Scholar 

  36. Smith AJ, Tett SE. How do different age groups use benzodiazepines and antidepressants? Analysis of an Australian administrative database, 2003–6. Drugs Aging. 2009;26(2):113–22.

    Article  CAS  PubMed  Google Scholar 

  37. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136–42.

    Article  PubMed  Google Scholar 

  38. Parsons C, Haydock J, Mathie E, Baron N, Machen I, Stevenson E, et al. Sedative load of medications prescribed for older people with dementia in care homes. BMC Geriatr. 2011;11:56.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Grohol JM. Top 25 psychiatric medication prescriptions for 2013. 2015. http://psychcentral.com/lib/top-25-psychiatric-medication-prescriptions-for-2013/. Accessed 15 April 2016.

  40. Lee KS, Kim SH, Hwang HJ. Behavioral and psychological symptoms of dementia and antipsychotic drug use in the elderly with dementia in Korean long-term care facilities. Drugs Real World Outcomes. 2015;2(4):363–8.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Pringsheim T, Gardner DM. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open. 2014;2(4):E225–32.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ. 2008;179(5):438–46.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio R, et al. Trends in antipsychotic use in dementia 1999–2007. Arch Gen Psychiatry. 2011;68(2):190–7.

    Article  PubMed  Google Scholar 

  44. Seitz DP, Brisbin S, Herrmann N, Rapoport MJ, Wilson K, Gill SS, et al. Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic review. J Am Med Dir Assoc. 2012;13(6):503–6.

    Article  PubMed  Google Scholar 

  45. Bozat-Emre S, Doupe M, Kozyrskyj AL, Grymonpre R, Mahmud SM. Atypical antipsychotic drug use and falls among nursing home residents in Winnipeg, Canada. Int J Geriatr Psychiatry. 2015;30(8):842–50.

    Article  PubMed  Google Scholar 

  46. Walsh JK, Erman M, Erwin CW, Jamieson A, Mahowald M, Regestein Q, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum Psychopharmacol. 1998;13(3):191–8.

    Article  CAS  Google Scholar 

  47. Haria M, Fitton A, McTavish D. Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994;4(4):331–55.

    Article  CAS  PubMed  Google Scholar 

  48. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Vigen CLP, Mack WJ, Keefe RSE, Sano M, Sultzer DL, Stroup TS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168(8):831–9.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J Am Med Assoc. 2005;294(15):1934–43.

    Article  CAS  Google Scholar 

  51. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303–12.

    Article  CAS  PubMed  Google Scholar 

  52. Kohen I, Gordon ML, Manu P. Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports. CNS Spectr. 2007;12(8):596–8.

    PubMed  Google Scholar 

  53. Mittur A. Trazodone: properties and utility in multiple disorders. Expert Rev Clin Pharmacol. 2011;4(2):181–96.

    Article  CAS  PubMed  Google Scholar 

  54. Cheer SM, Wagstaff AJ. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs. 2004;18(3):173–99.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

These datasets were linked using unique encoded identifiers and analyzed at ICES. The authors thank Brogan Inc., Ottawa, for the use of their Drug Product and Therapeutic Class Database. Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions, and statements expressed herein are those of the authors, and not necessarily those of CIHI.

Author information

Authors and Affiliations

  1. Centre for Mental Health, University Health Network, Toronto, ON, Canada

    Andrea Iaboni & Alastair J. Flint

  2. Department of Psychiatry, University of Toronto, Toronto, ON, Canada

    Andrea Iaboni, Katelyn B. Reynolds, Nathan Herrmann & Alastair J. Flint

  3. Institute for Clinical Evaluative Sciences, Toronto, ON, Canada

    Susan E. Bronskill, Xuesong Wang & Paula A. Rochon

  4. Institute of Health, Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada

    Susan E. Bronskill & Paula A. Rochon

  5. Women’s College Research Institute, Women’s College Hospital, Toronto, ON, Canada

    Paula A. Rochon

  6. Department of Medicine, University of Toronto, Toronto, ON, Canada

    Paula A. Rochon

  7. Hurvitz Brain Sciences Program Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Nathan Herrmann

  8. Toronto Rehabilitation Institute, 550 University Ave, 5-105-3, Toronto, ON, M5G 2A2, Canada

    Andrea Iaboni

Authors
  1. Andrea Iaboni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan E. Bronskill
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katelyn B. Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xuesong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paula A. Rochon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nathan Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alastair J. Flint
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Iaboni.

Ethics declarations

Funding

This work was supported by a Grant from the University Health Network Psychiatric Consultants Research Fund and a Team Grant (OTG-88591) from the Canadian Institutes of Health Research (CIHR) Institute of Nutrition, Metabolism, and Diabetes. This study was also supported by ICES, which is funded by an annual Grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.

Conflict of interest

AI, KBR, and XW have no conflicts of interest or financial disclosures. SEB, in the past 2 years, has received Grant support from the CIHR and the Technology Evaluation in the Elderly (TVN) National Centre for Excellence. PAR, in the past 2 years, has received Grant support from the CIHR and the Ontario Institute for Cancer Research. NH has received research funding and consultant fees from Lundbeck, Roche, Abbvie, Astellas, Merck, and Lilly. AF, in the past 2 years, has received Grant support from the National Institute of Mental Health, the CIHR, the Ontario Brain Institute, the Buchan Foundation, Lundbeck, and Servier. He has also received honoraria from Pfizer Canada.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 19 kb)

Supplementary material 2 (DOCX 537 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iaboni, A., Bronskill, S.E., Reynolds, K.B. et al. Changing Pattern of Sedative Use in Older Adults: A Population-Based Cohort Study. Drugs Aging 33, 523–533 (2016). https://doi.org/10.1007/s40266-016-0380-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-016-0380-3

Keywords

Search

Navigation